What question did this study set out to answer?

Determine whether incorporating idarubicin, fludarabine, or interleukin-2 into intensive chemotherapy regimens improves clinical outcomes in untreated pediatric acute myeloid leukemia.

November 14, 2007BloodOpen Access

Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

View Full Paper

Ask AI

Bookmark

Authors

BLBeverly J. LangeChildren's Hospital of Philadelphia FSFranklin O. SmithMedpace (United States)JFJames H. FeusnerUCSF Benioff Children's Hospital

Discussion

Member takes

Implication

Randomized trial reveals improved overall survival and declining toxicity in pediatric acute myeloid leukemia, suggesting supportive care advances drive progress rather than new chemotherapy agents.

Key Points

Determine whether incorporating idarubicin, fludarabine, or interleukin-2 into intensive chemotherapy regimens improves clinical outcomes in untreated pediatric acute myeloid leukemia.
Enrolled 901 patients under age 21 years with untreated acute myeloid leukemia in the multicenter Children's Oncology Group phase 3 trial CCG-2961.
Administered intensive-timing induction substituting idarubicin for daunomycin, followed by randomized postremission chemotherapy (5-drug reinduction vs fludarabine, cytarabine, and idarubicin) and allogeneic marrow transplantation or high-dose cytarabine with or without randomized interleukin-2.
Overall 5-year survival reached 52% and event-free survival was 42%, with survival improving from 44% (1996–1998) to 58% (2000–2002; P = .005) alongside a reduction in treatment-related mortality from 19% to 12% (P = .025).
Postremission survival was 56% in both the 5-drug reinduction and fludarabine/cytarabine/idarubicin arms, while interleukin-2 administration after cytarabine intensification conferred no outcome benefit.
Patients with a related marrow donor achieved significantly higher 5-year disease-free survival than those without a donor (61% vs 50%, P = .021), whereas overall survival did not differ significantly (68% vs 62%, P = .425).

Cite This Study

Lange et al. (2007) studied this question.

synapsesocial.com/papers/6a10cabd497e609eda6456dd https://doi.org/10.1182/blood-2007-04-084293

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals improved overall survival and declining toxicity in pediatric acute myeloid leukemia, suggesting supportive care advances drive progress rather than new chemotherapy agents.

Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

Discussion

Member takes

Implication

Key Points

Cite This Study

Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider